Results from a series of focus group discussions revealed donors, collection staff, and physicians supported iron supplementation if donors were given freedom of choice and necessary information about iron deficiency and supplementation.
On the floor at HFSA 2023, Muthiah Vaduganathan, MD, MPH, provides his perspective on the latest IV iron supplementation guidelines from the European Society of Cardiology.
Using iron therapy optimally bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.
1. This noninferiority trial found that at 12 weeks, hematologic responses to 200 mg ferrous fumarate thrice weekly (TIW) were not significantly different than the TID iron treatment group for iron deficiency anemia (IDA) by week 12 of treatment. Evidence Rating Level: 1 (Excellent) IDA is a relatively common condition affecting patients' quality of life.
1. Although anemia prevalence at 36 weeks was slightly lower in the ferric carboxymaltose group compared to standard-of-care, statistical significance was not achieved. 2. Adverse events between both groups were comparable; there were no changes in birth weight. Evidence Rating Level: 1 (Excellent) Study Rundown: Anemia affects more than one-third of all pregnancies in Africa.